{"id":743819,"date":"2013-02-22T08:30:00","date_gmt":"2013-02-22T08:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-analyses-of-its-investigational-ragweed-pollen-and-grass-pollen-allergy-immunotherapy-tablets\/"},"modified":"2023-03-22T00:04:41","modified_gmt":"2023-03-22T04:04:41","slug":"merck-to-present-new-data-analyses-of-its-investigational-ragweed-pollen-and-grass-pollen-allergy-immunotherapy-tablets","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-analyses-of-its-investigational-ragweed-pollen-and-grass-pollen-allergy-immunotherapy-tablets\/","title":{"rendered":"Merck to Present New Data Analyses of its Investigational Ragweed Pollen and Grass Pollen Allergy Immunotherapy Tablets"},"content":{"rendered":"<p>\n      Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that researchers will present new data analyses of the<br \/>\n      safety and efficacy of the company\u2019s investigational allergy<br \/>\n      immunotherapy tablets (AITs) for ragweed pollen (<i>Ambrosia<br \/>\n      artemisiifolia<\/i>) and grass pollen (<i>Phleum pratense<\/i>) at the<br \/>\n      2013 American Academy of Allergy, Asthma &#038; Immunology (AAAAI) Annual<br \/>\n      Meeting. The meeting will be held in San Antonio from February 22-26.\n    <\/p>\n<p>\n      Merck&#8217;s AIT products are investigational, dissolvable oral tablets<br \/>\n      designed to help treat the underlying cause of allergic rhinitis by<br \/>\n      generating an immune response to help protect against targeted<br \/>\n      allergens. Merck has partnered with ALK-Abello to develop AITs in North<br \/>\n      America. Earlier this year, Merck submitted a Biologics License<br \/>\n      Application (BLA) for its grass pollen AIT to the U.S. Food and Drug<br \/>\n      Administration (FDA), and Merck plans to submit a BLA for its ragweed<br \/>\n      pollen AIT to the FDA later in 2013.\n    <\/p>\n<p>\n      \u201cWe are pleased to present new results for Merck\u2019s investigational AIT<br \/>\n      products to the scientific community that we believe will be valuable in<br \/>\n      thinking about immunotherapy and the treatment of allergic rhinitis,\u201d<br \/>\n      said Jeffrey A. Chodakewitz, M.D., senior vice president, Global<br \/>\n      Scientific Strategy, franchise head, Infectious Diseases and interim<br \/>\n      franchise head, Respiratory &#038; Immunology, Merck Research Laboratories.<br \/>\n      \u201cMerck is committed to research in the area of allergic rhinitis.\u201d\n    <\/p>\n<p>\n      <b>Select Merck Presentations at AAAAI<\/b>\n    <\/p>\n<p>\n      <b>Sunday, Feb. 24, 2013 9:45 a.m.-10:45 a.m., Poster Session 3209,<br \/>\n      Exhibit Hall C<\/b>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        <b>403:<\/b> Characterizing the 12 Amb a 1-U Ragweed Allergy<br \/>\n        Immunotherapy Tablet Adverse Event Profile in Adults with<br \/>\n        Ragweed-Induced Allergic Rhinoconjunctivitis\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <b>405:<\/b> Safety of Ragweed Allergy Immunotherapy Tablet: Results<br \/>\n        From Four Placebo-Controlled Trials\n      <\/li>\n<\/ul>\n<p>\n      <b>Tuesday, Feb. 26, 2013 9:45 a.m.-10:45 a.m., Poster Session 5206,<br \/>\n      Exhibit Hall C<\/b>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        <b>809: <\/b>Ragweed Allergy Immunotherapy Tablet Reduces Use of Ocular<br \/>\n        Antihistamines in Patients With Ragweed Pollen\u2013Induced Allergic<br \/>\n        Rhinoconjunctivitis\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <b>810:<\/b> Effect of Allergy Immunotherapy Tablet in Patients with or<br \/>\n        without Local Application-Site Reactions\n      <\/li>\n<\/ul>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&#038;esheet=50572976&#038;lan=en-US&#038;anchor=vip2-msd.com\/merckcom-migrated&#038;index=1&#038;md5=c8d02117427f7dd1b26cd12f14052ca9\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on Twitter, Facebook and YouTube.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2011 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov&#038;esheet=50572976&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=2&#038;md5=0dac54efada1d0ae6a0d54642c952b6a\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&#038;sty=20130222005090r1&#038;sid=sfsite1&#038;distro=nx\" \/><span class=\"bwct31415\"\/><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pam Eisele, 908-423-5042<br \/>or<br \/>Lesley        Brown, 267-305-3545<br \/>or<br \/>Investor:<br \/>Carol Ferguson,        908-423-4465<br \/>or<br \/>Justin Holko, 908-423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that researchers will present new data analyses of the safety and efficacy of the company\u2019s investigational allergy immunotherapy tablets (AITs) for ragweed pollen ( Ambrosia artemisiifolia ) and grass pollen ( Phleum pratense ) at the 2013 American Academy of Allergy, Asthma &#038; Immunology (AAAAI) Annual Meeting. The meeting will be held in San Antonio from February 22-26. Merck&#8217;s AIT products are investigational, dissolvable oral tablets designed to help treat the underlying cause of allergic rhinitis by generating an immune response to help protect against targeted allergens. Merck has partnered with ALK-Abello to develop AITs in North America. Earlier this year, Merck submitted a Biologics License Application (BLA) for its grass pollen AIT to the U.S. Food and Drug Administration (FDA), and Merck plans to submit a BLA for its ragweed pollen AIT to the FDA later in 2013. \u201cWe are pleased to present<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,289,56],"class_list":["post-743819","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck to Present New Data Analyses of its Investigational Ragweed Pollen and Grass Pollen Allergy Immunotherapy Tablets - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-analyses-of-its-investigational-ragweed-pollen-and-grass-pollen-allergy-immunotherapy-tablets\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck to Present New Data Analyses of its Investigational Ragweed Pollen and Grass Pollen Allergy Immunotherapy Tablets - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that researchers will present new data analyses of the safety and efficacy of the company\u2019s investigational allergy immunotherapy tablets (AITs) for ragweed pollen ( Ambrosia artemisiifolia ) and grass pollen ( Phleum pratense ) at the 2013 American Academy of Allergy, Asthma &amp; Immunology (AAAAI) Annual Meeting. The meeting will be held in San Antonio from February 22-26. Merck&#039;s AIT products are investigational, dissolvable oral tablets designed to help treat the underlying cause of allergic rhinitis by generating an immune response to help protect against targeted allergens. Merck has partnered with ALK-Abello to develop AITs in North America. Earlier this year, Merck submitted a Biologics License Application (BLA) for its grass pollen AIT to the U.S. Food and Drug Administration (FDA), and Merck plans to submit a BLA for its ragweed pollen AIT to the FDA later in 2013. \u201cWe are pleased to present\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-analyses-of-its-investigational-ragweed-pollen-and-grass-pollen-allergy-immunotherapy-tablets\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:41+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130222005090r1&sid=sfsite1&distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-new-data-analyses-of-its-investigational-ragweed-pollen-and-grass-pollen-allergy-immunotherapy-tablets\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-new-data-analyses-of-its-investigational-ragweed-pollen-and-grass-pollen-allergy-immunotherapy-tablets\\\/\",\"name\":\"Merck to Present New Data Analyses of its Investigational Ragweed Pollen and Grass Pollen Allergy Immunotherapy Tablets - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-new-data-analyses-of-its-investigational-ragweed-pollen-and-grass-pollen-allergy-immunotherapy-tablets\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-new-data-analyses-of-its-investigational-ragweed-pollen-and-grass-pollen-allergy-immunotherapy-tablets\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20130222005090r1&sid=sfsite1&distro=nx\",\"datePublished\":\"2013-02-22T08:30:00+00:00\",\"dateModified\":\"2023-03-22T04:04:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-new-data-analyses-of-its-investigational-ragweed-pollen-and-grass-pollen-allergy-immunotherapy-tablets\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-new-data-analyses-of-its-investigational-ragweed-pollen-and-grass-pollen-allergy-immunotherapy-tablets\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-new-data-analyses-of-its-investigational-ragweed-pollen-and-grass-pollen-allergy-immunotherapy-tablets\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20130222005090r1&sid=sfsite1&distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20130222005090r1&sid=sfsite1&distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-new-data-analyses-of-its-investigational-ragweed-pollen-and-grass-pollen-allergy-immunotherapy-tablets\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck to Present New Data Analyses of its Investigational Ragweed Pollen and Grass Pollen Allergy Immunotherapy Tablets\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck to Present New Data Analyses of its Investigational Ragweed Pollen and Grass Pollen Allergy Immunotherapy Tablets - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-analyses-of-its-investigational-ragweed-pollen-and-grass-pollen-allergy-immunotherapy-tablets\/","og_locale":"en_US","og_type":"article","og_title":"Merck to Present New Data Analyses of its Investigational Ragweed Pollen and Grass Pollen Allergy Immunotherapy Tablets - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that researchers will present new data analyses of the safety and efficacy of the company\u2019s investigational allergy immunotherapy tablets (AITs) for ragweed pollen ( Ambrosia artemisiifolia ) and grass pollen ( Phleum pratense ) at the 2013 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. The meeting will be held in San Antonio from February 22-26. Merck's AIT products are investigational, dissolvable oral tablets designed to help treat the underlying cause of allergic rhinitis by generating an immune response to help protect against targeted allergens. Merck has partnered with ALK-Abello to develop AITs in North America. Earlier this year, Merck submitted a Biologics License Application (BLA) for its grass pollen AIT to the U.S. Food and Drug Administration (FDA), and Merck plans to submit a BLA for its ragweed pollen AIT to the FDA later in 2013. \u201cWe are pleased to present","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-analyses-of-its-investigational-ragweed-pollen-and-grass-pollen-allergy-immunotherapy-tablets\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:41+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130222005090r1&sid=sfsite1&distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-analyses-of-its-investigational-ragweed-pollen-and-grass-pollen-allergy-immunotherapy-tablets\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-analyses-of-its-investigational-ragweed-pollen-and-grass-pollen-allergy-immunotherapy-tablets\/","name":"Merck to Present New Data Analyses of its Investigational Ragweed Pollen and Grass Pollen Allergy Immunotherapy Tablets - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-analyses-of-its-investigational-ragweed-pollen-and-grass-pollen-allergy-immunotherapy-tablets\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-analyses-of-its-investigational-ragweed-pollen-and-grass-pollen-allergy-immunotherapy-tablets\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130222005090r1&sid=sfsite1&distro=nx","datePublished":"2013-02-22T08:30:00+00:00","dateModified":"2023-03-22T04:04:41+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-analyses-of-its-investigational-ragweed-pollen-and-grass-pollen-allergy-immunotherapy-tablets\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-analyses-of-its-investigational-ragweed-pollen-and-grass-pollen-allergy-immunotherapy-tablets\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-analyses-of-its-investigational-ragweed-pollen-and-grass-pollen-allergy-immunotherapy-tablets\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130222005090r1&sid=sfsite1&distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20130222005090r1&sid=sfsite1&distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-analyses-of-its-investigational-ragweed-pollen-and-grass-pollen-allergy-immunotherapy-tablets\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck to Present New Data Analyses of its Investigational Ragweed Pollen and Grass Pollen Allergy Immunotherapy Tablets"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"3fe929fb-38af-4822-86d3-90ccfbefc8de","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/743819","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/743819\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=743819"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=743819"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}